BioGend Therapeutics Co., Ltd. (TPEX:6733)
Taiwan · Delayed Price · Currency is TWD 25.95
+0.20 (0.78%)
May 29, 2026, 1:30 PM CST
BioGend Therapeutics Market Cap
BioGend Therapeutics has a market cap or net worth of 3.23 billion as of May 29, 2026. Its market cap has decreased by -6.75% in one year.
Market Cap
3.23B
Enterprise Value
2.38B
Revenue
229.81M
Ranking
n/a
PE Ratio
n/a
Stock Price
25.95
Market Cap Chart
Since June 18, 2019, BioGend Therapeutics's market cap has increased from 2.71B to 3.23B, an increase of 18.89%. That is a compound annual growth rate of 2.52%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| May 29, 2026 | 3.23B | -32.42% |
| Dec 31, 2025 | 4.78B | 14.21% |
| Dec 31, 2024 | 4.18B | -11.18% |
| Dec 29, 2023 | 4.71B | 109.50% |
| Dec 30, 2022 | 2.25B | -18.50% |
| Dec 30, 2021 | 2.76B | -22.86% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro |
| Jun 18, 2019 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| OBI Pharma | 3.71B |
| Sagittarius Life Science | 3.66B |
| Energenesis Biomedical CO.,LTD. | 3.40B |
| Shine-On BioMedical | 3.20B |
| SYN-TECH Chem. & Pharm. | 3.19B |
| Chunghwa Chemical Synthesis & Biotech | 3.07B |
| Genovate Biotechnology | 3.03B |
| Apex Biotechnology | 2.99B |